WARSAW, Ind., Feb. 01, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the publication of an Environmental, Social, and Governance (“ESG”) summary report. The report highlights how the Company’s commitment to diversity, inclusion and ethics underscores its mission to transform the lives of children with orthopedic conditions and provides a baseline of key ESG performance metrics.
“At OrthoPediatrics we live our Company cause every day,” said David Bailey, President and CEO of OrthoPediatrics. “Part of our work serving a patient population that has historically been underserved by the industry is ensuring that KIDS all over the world have access to world-class technologies that were previously unavailable. The other part of our work is affecting lasting and meaningful change in the organizations with whom we engage, which we have found unites our employees with a powerful sense of purpose while driving our business forward. We are excited to share our commitment and progress as ESG stewards.”
Key highlights from this year’s report include:
The full ESG report is available on the Company’s website at https://www.orthopediatrics.com/about-us/environmental-social-governance/.
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 46 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com.
Investor Contact
Philip Trip Taylor
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
415-937-5406
Last Trade: | US$22.89 |
Daily Change: | -0.49 -2.10 |
Daily Volume: | 97,019 |
Market Cap: | US$554.400M |
November 26, 2024 November 06, 2024 August 05, 2024 August 05, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB